{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:04:51Z","timestamp":1785769491494,"version":"3.56.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and importance:<\/jats:title>\n                    <jats:p>Ocrelizumab, an anti-CD20 monoclonal antibody for multiple sclerosis (MS), has a generally favorable safety profile; however, acute pancreatitis is a rare and under-recognized adverse event. Awareness of this potential association is important to ensure timely diagnosis and reporting in patients on ocrelizumab who present with abdominal symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>A 57-year-old man with MS receiving 6-monthly ocrelizumab injections presented with 3\u00a0days of epigastric pain radiating to the back, with nausea and vomiting. He denied recent alcohol use and had no history of gallstones. Laboratory tests showed lipase 854\u00a0U\/L (10\u2013140) and amylase 528\u00a0U\/L (30\u2013110) with otherwise unremarkable liver enzymes, calcium, lipids, and IgG subclasses. Abdominal ultrasound demonstrated no cholelithiasis, biliary or pancreatic duct dilatation, or peripancreatic collection. His medications included carbamazepine (commenced 5\u00a0years earlier without prior pancreatitis) and folic acid. Symptoms improved with conservative management, and he was discharged with outpatient follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical discussion:<\/jats:title>\n                    <jats:p>Drug-induced pancreatitis accounts for approximately 2% of acute pancreatitis cases. In clinical trials of ocrelizumab (OPERA I\/II, ORATORIO), a handful of pancreatitis cases were reported, some with alternative risk factors; others occurred without gallstones or hypertriglyceridemia. The mechanism remains uncertain but may relate to immune dysregulation following B-cell depletion with downstream T-cell-mediated inflammation. Using the Naranjo scale, this case scores as a \u201cpossible\u201d adverse drug reaction. Based on Badalov classification, ocrelizumab aligns with Class III, reflecting limited published data and no rechallenge evidence. Concomitant carbamazepine remains an important confounder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pancreatitis should be considered in ocrelizumab-treated patients presenting with abdominal pain, even when routine risk factors are absent. Early recognition enables appropriate management and contributes to a growing evidence base needed to clarify pathophysiology and refine risk stratification for this uncommon adverse event.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rc9.0000000000000232","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:01:10Z","timestamp":1770800470000},"page":"976-979","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ocrelizumab-induced acute pancreatitis: case report of an uncommon side effect of multiple sclerosis treatment"],"prefix":"10.1097","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-2334","authenticated-orcid":false,"given":"Sam","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Surgery, Campbelltown Hospital, Sydney, NSW, Australia"},{"name":"University of New South Wales, School of Medicine, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Selvendran","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campbelltown Hospital, Sydney, NSW, Australia"},{"name":"University of New South Wales, School of Medicine, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"1136\u201340","DOI":"10.1097\/JS9.0000000000000373","article-title":"The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"109","author":"Sohrabi","year":"2023","journal-title":"Int J Surg"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"102\u201311","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20142012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"239\u201345","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"648\u201361","DOI":"10.1016\/j.cgh.2006.11.023","article-title":"Drug-induced acute pancreatitis: an evidence-based review","volume":"5","author":"Badalov","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"143\u201355","DOI":"10.1016\/j.bpg.2010.02.002","article-title":"Drug induced pancreatitis","volume":"24","author":"Nitsche","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R6-20260803","first-page":"45\u201351","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"361\u201371","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"key":"R8-20260803","first-page":"423\u201333","article-title":"Ocrelizumab: its efficacy and safety in multiple sclerosis","volume":"66","author":"Juanatey","year":"2018","journal-title":"Rev Neurol"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1093\/ibd\/izaa057","article-title":"First Case of Refractory Colitis Caused by Ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"597\u2013605","DOI":"10.1093\/intimm\/12.5.597","article-title":"Regulatory Role of Mature B Cells in a Murine Model of Inflammatory Bowel Disease","volume":"12","author":"Mizoguchi","year":"2000","journal-title":"Int Immunol"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"102381","DOI":"10.1016\/j.msard.2020.102381","article-title":"Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis","volume":"45","author":"Adamec","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RC9.0000000000000232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:12:59Z","timestamp":1785766379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RC9.0000000000000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rc9.0000000000000232","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"2025-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}